Brief: Novakand Board Proposes New Business Direction, Relisting
02/03/2026 06:05
March 2 (Reuters) - Novakand Pharma AB NOVKAN.ST: CO'S BOARD OF DIRECTORS PROPOSES NEW BUSINESS DIRECTION AND RELISTING TO BE PRESENTED AT EXTRAORDINARY GENERAL MEETING CONTACTED CERTAIN MAJOR SHAREHOLDERS INDIVIDUALLY TO SECURE A BROADER SHAREHOLDER BASE FOR DECISIONS NOT POSSIBLE TO ADVANCE FRACTALKINE PROGRAM WITHIN CURRENT LEAD INDICATIONS BELIEVES BEST WAY FORWARD IS TO EVALUATE FRACTALKINE PROGRAM IN NISCHE INDICATIONS TAKING STEPS TO PREPARE FOR AN APPLICATION FOR RELISTING BOARD TO CONVENE EGM FOR NEW BUSINESS DIRECTION AND RELISTING CONDITIONS FOR RAISING SEK 150-300 MILLION FOR PHASE II TRIAL LACKING Source text: ID:nMFN9MQjGy Further company coverage: NOVKAN.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novakand Pharma AB
See all newsBrief: Nasdaq Decides To Delist Novakand From First North Growth Market
Brief: Novakand Pharma Extends Peter Selin's CEO Employment
Brief: Novakand Board Proposes New Business Direction, Relisting
Brief: Novakand Pharma Evaluates Options After Decision Not To Execute Reverse Take Over
Brief: Nasdaq Rejects Novakand's Application For Continued Listing